Real-world incidence of patient-reported dyspnoea with ticagrelor

about

Real-world incidence of patient-reported dyspnoea with ticagrelor

Item

http://www.wikidata.org/entity/Q57134527

description

scientific article published on 09 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en-gb

Real-world incidence of patient-reported dyspnoea with ticagrelor

@nl

type

Item

label

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en-gb

Real-world incidence of patient-reported dyspnoea with ticagrelor

@nl

prefLabel

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en-gb

Real-world incidence of patient-reported dyspnoea with ticagrelor

@nl

P1476

Real-world incidence of patient-reported dyspnoea with ticagrelor

@en

P2093

Jessica L Dawson

http://www.w3.org/2001/XMLSchema#string

Karen M O'Kane

http://www.w3.org/2001/XMLSchema#string

KethLyn Koo

http://www.w3.org/2001/XMLSchema#string

P2860

Dyspnoea management in acute coronary syndrome patients treated with ticagrelor

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.

Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.

Variability in platelet responsiveness to clopidogrel among 544 individuals.

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)

P304

577-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2042098618788991

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30283625

http://www.w3.org/2001/XMLSchema#string

P932

6166316

http://www.w3.org/2001/XMLSchema#string